Abstract
Mycosis fungoides (MF) and Sézary Syndrome (SS) are the most common subtypes of cutaneous T cell lymphomas (CTCL). Advanced-stage MF/SS have poor prognoses and may be refractory to multiple systemic treatments. These cases can be difficult to achieve and maintain complete response and there is a need for novel therapeutics. Inhibition of the phosphatidylinositol 3-kinase (PI3K) pathway by Tenalisib presents one such emerging drug. We report a relapsed/refractory SS patient achieving complete remission using the combination of Tenalisib and Romidepsin and subsequently maintaining long-duration CR with Tenalisib monotherapy.
Original language | English (US) |
---|---|
Pages (from-to) | 350-355 |
Number of pages | 6 |
Journal | Investigational New Drugs |
Volume | 41 |
Issue number | 2 |
DOIs | |
State | Published - Apr 2023 |
Keywords
- Cutaneous T Cell Lymphoma
- Mycosis Fungoides
- Refractory
- Sézary Syndrome
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Pharmacology (medical)